Form 4: Aptevo Therapeutics Director Zsolt Harsanyi Acquires Restricted Stock Units

Director Zsolt Harsanyi acquired 925 Restricted Stock Units (RSUs) of Aptevo Therapeutics Inc. on July 17, 2024, which vest in full on the first anniversary of the grant date.

Summary

• On July 17, 2024, Zsolt Harsanyi, a director of Aptevo Therapeutics Inc., acquired 925 Restricted Stock Units (RSUs).
• These RSUs convert into common stock on a one-for-one basis.
• The RSUs vest fully on the first anniversary of the grant date.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it simply reports a transaction. The acquisition of stock by a director is generally viewed as a positive sign, but without additional context, the impact is limited.

Positives

• The acquisition of RSUs by a director may signal confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This filing is a routine disclosure of a director's acquisition of company stock, which is common in the pharmaceutical industry as part of executive compensation packages.

Stakeholder Impact

• Shareholders may view the director's acquisition of RSUs as a positive sign of confidence in the company's future.

Key Dates

Keywords

Aptevo Therapeutics, Director, Zsolt Harsanyi, Restricted Stock Units, RSUs, Beneficial Ownership, Form 4, Securities, Acquisition, Vesting